JEFFERSON DE JESUS SILVA
2 resultados
Resultados de Busca
Agora exibindo 1 - 2 de 2
Resumo IPEN-doc 26856 177Lu-PSMA-6172019 - BOAS, CRISTIAN W.V.; SILVA, JEFFERSON de J.; BENEDETTO, RAQUEL; MENGATTI, JAIR; ARAUJO, ELAINE B. deIntroduction: PSMA-617 radiolabeled with lutetium-177 has shown good results in compassionate studies around the world, and there is great interest in this kind of therapy in Brazil. The Nuclear and Research Institute (IPEN-CNEN) in São Paulo city, is a national radiopharmaceutical producer and the distribution of radiopharmaceuticals for therapy in a country of continental dimensions such as Brazil, becomes a challenge from the standpoint of guaranteeing the stability of the product. This work evaluated the scheduling of pilot batches for the production of 177Lu-PSMA-617 and studied the effect of dilution and freezing on the stability of mono-doses of the product. Materials and Methods: Radiolabeling of PSMA-617 (ABX, Germany) with lutetium-177 (JSC, Russia) was performed in heating block at 90 °C for 30 minutes, 37 GBq (1 Ci), 500 μg of peptide and sodium ascorbate (0,5 M pH 4,7) as buffer. At the end of the radiolabel, 0,5 mL of DTPA solution (4 mg/mL pH 4,5) was added and the product was diluted with an appropriate volume of saline solution 0,9%. The final product was filtrated in 0.22 membrane and the doses were fractionated (7,4 GBq calibrated for 24 hours in approximately 2,4 mL) and conditioned in appropriate lead chambers inside a dry ice bucket for transport simulation. The radiochemical purity (RP) was evaluated in a stability study at, 24 and 48 hours by TLC and HPLC. The radionuclidic purity, sterility and bacterial endotoxins were also evaluated. Results and discussion: The radiopharmaceutical was stable after 48 hours (99.47% TLC and 99.39% HPLC), and was approved in radionuclidic, sterility and endotoxins assays. The vials fractionated in mono-doses calibrated for 24 hours showed high stability through freezing and dilution, which allowed the transportation to the Cancer Hospital of Barretos, distant 420 km from the production center in São Paulo. All these mono-doses were administrated to the patients after 24 hours of the production. Also, these results denote that is possible to scale up this production until 74 GBq and be used in a clinical trial that is being planned. Conclusions: These carried out experiments demonstrated that it is possible to produce 177Lu-PSMA-617 for use in clinical trials in Brazil. Until now, four patients are under treatment (compassionate use). Also, these results demonstrate that it is still possible to increase production activity to 74 GBq, just like is normally done with 177Lu-DOTATATE.Artigo IPEN-doc 24713 Development of radioimmunoconjugate for diagnosis and management of head-and-neck subclinical cancer and colorectal carcinoma2018 - BENEDETTO, RAQUEL; MASSICANO, ADRIANA V.F.; SILVA, JEFFERSON J.; BOAS, CRISTIAN A.W.V.; MENGATTI, JAIR; ARAUJO, ELAINE B. deScientific innovations in diagnostic methods are important drivers of cancer control and prevention. Noninvasive imaging of the epidermal growth factor receptor (EGFR) in head-and-neck squamous, cell carcinoma and colorectal cancer could be valuable to select patients for EGFR-targeted therapy, as well as to monitor the efficacy and occurrence of resistance to immunotherapy. In order to develop the first Brazilian radioimmunoconjugate for diagnosis, Cetuximab has been conjugated to p-SCN-Bn-DTPA chelator and radiolabeled with Indium-111. The conjugation methodology was optimized using different mAb:DTPA molar ratios, time was then reduced for immunoconjugate preparation, besides the protein recovery’ percentage increased after purification (m = 83.8 ± 0.91 %). The stability of Cetuximab-DTPA at – 20 oC was evaluated for six months, and its integrity was greater than 90% (m =93.9 ± 1.5%, N = 24). The radioimmunoconjugate with specific activity of 185 MBq/mg showed radiochemical purity above 95% (m=96.8 ± 1.31 %, N = 15). We conclude that the radioimmunoconjugate 111In-DTPA-cetuximab is stable and may be applied to the diagnosis of EGFR-positive tumors.